Transcatheter Cardiovascular Therapeutics industry round-up April 2006

FDA happenings: More QC troubles at Guidant; Label expansion for Medtronic CRTs; FDA announces Critical Path opportunities list; and more

Around the industry: Boston Scientific-Guidant merger cleared by FTC; Guidant suspends use of Xience V; Conor licenses pimecrolimus from Novartis; and more

Proceedings of TCT 3, 21-24 (2006).
view PDF
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: